Back to Global NewsPublished: 23 Feb 2026Download AppJoin TelegramWhy Novo Nordisk's Obesity Drug Miss Is a Red Flag for Weight‑Loss Investors#Novo Nordisk#Eli Lilly#obesity drug#weight loss market#pharma stocks#clinical trial#investmentDownload AppJoin CommunityShare Article